Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of diabetes mellitus, type 2 within 12 months prior to screening~* Patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past~* HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit~* Fasting plasma glucose \</=240 mg/dL at pre-randomization visit~* Agreement to maintain diet and exercise habits during the study~Exclusion Criteria:~* Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months~* Any previous treatment with thiazolidinedione or a dual peroxisome proliferator activated receptor (PPAR) agonist~* Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)~* Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- aleglitazar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).